Global biopharmaceutical company AstraZeneca has formed a partnership with the National Comprehensive Cancer Network® Oncology Research Program seeking proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer (NSCLC). The collaborative partnership is inviting researchers from NCCN’s 28 member institutions to submit a letter of intent by July 9 2019. The team notes all funded programs must:

  • Promote evidence-based care
  • Be sustainable after the award funding is complete
  • Collect data and report outcomes
  • Aim to enhance clinical outcomes, patient satisfaction, or provider satisfaction
  • Address patient variability
  • Promote administrative and system efficiency
Source: Prnewswire.

Pin It on Pinterest